Education
About Us
Working with TipRanks
Follow Us
InfuSystem Holdings, Inc. (INFU)
:INFU
RESEARCH TOOLSreports
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.04Last Year’s EPS
0.03Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 28.63%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Positive
InfuSystem demonstrated strong revenue growth and improved profitability despite some challenges related to IT upgrade costs and specific segment performance. The outlook remains positive with expectations of continued growth and margin improvement.Company Guidance
During the first quarter of 2025, InfuSystem Holdings, Inc. reported an 8.5% increase in revenue, reaching $34.7 million. The company's adjusted EBITDA grew by 64% year-over-year to $6.3 million, yielding an 18.2% margin, a significant rise from 12.1% in the previous year. Operating cash flow improved to $1.8 million, nearly quadrupling the previous year's first quarter. The Patient Services segment led revenue growth with an 11.7% increase, while the Device Solutions segment rose by 4%. Gross margin improved to 55.2%, driven by better revenue mix and improved third-party payer collections. Despite incurring $500,000 in IT upgrade expenses, the company maintained strong profitability. InfuSystem expects full-year revenue growth between 8% and 10%, with an adjusted EBITDA margin exceeding the 18.8% recorded in 2024.Revenue Growth
InfuSystem reported an 8.5% increase in revenue for Q1 2025, driven by diversified business activities and despite limited contributions from growth initiatives like Advanced Wound Care and Chemo Mouthpiece.
Adjusted EBITDA Surge
The company experienced a 64% year-over-year increase in adjusted EBITDA, reaching $6.3 million, with an adjusted EBITDA margin of 18.2%, the highest since Q1 2021.
Strong Performance in Patient Services Segment
The Patient Services segment saw a 11.7% increase in net revenues, with growth across all therapies, including a 10.3% increase in oncology net revenue and a 33% rise in wound care treatment revenue.
Improved Cash Flow
Operating cash flow improved significantly to $1.8 million, nearly four times higher than the prior year first quarter.
Positive Outlook for Full Year
InfuSystem expects full-year growth of 8% to 10% in net revenues and an adjusted EBITDA margin higher than the previous year's 18.8%.
INFU Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
INFU Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $4.75 | $5.47 | +15.16% |
Mar 04, 2025 | $7.26 | $6.47 | -10.88% |
Nov 07, 2024 | $6.98 | $7.34 | +5.16% |
Aug 08, 2024 | $5.80 | $6.00 | +3.45% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does InfuSystem Holdings, Inc. (INFU) report earnings?
InfuSystem Holdings, Inc. (INFU) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is InfuSystem Holdings, Inc. (INFU) earnings time?
InfuSystem Holdings, Inc. (INFU) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INFU EPS forecast?
INFU EPS forecast for the fiscal quarter 2025 (Q2) is 0.04.